Ownership and insider activity for Invivyd, Inc. (IVVD): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease.
Price
| Price | $0.81 |
| Market Cap | $237M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $115.0M | $542.2M | $92.1M | $200.6M | $69.3M | $226.7M |
| Short-term Investments | 0 | $49.2M | $279.9M | 0 | 0 | 0 |
| Receivables | 0 | $229000 | $377000 | $933000 | $11.2M | $14.6M |
| Inventory | 0 | 0 | 0 | 0 | 0 | $25.5M |
| Total Current Assets | $117.4M | $616.7M | $376.9M | $224.9M | $100.7M | $247.5M |
| Property, Plant & Equipment | 0 | $83000 | $6.1M | $4.1M | $2.9M | $3.8M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $117.4M | $620.1M | $383.2M | $229.2M | $129.5M | $276.9M |
| Accounts Payable | $8.2M | $5.8M | $1.5M | $8.0M | $10.4M | $13.7M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $13.1M | $62.1M | $25.0M | $50.3M | $62.0M | $34.2M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $182.6M | $62.1M | $27.2M | $51.7M | $62.0M | $35.3M |
| Retained Earnings | -$65.3M | -$292.1M | -$533.4M | -$732.1M | -$902.0M | -$954.5M |
| Total Equity | -$65.2M | $558.0M | $356.0M | $177.5M | $67.5M | $241.5M |
| Total Debt | 0 | 0 | $3.7M | $2.2M | $1.3M | $2.5M |
| Net Debt | -$115.0M | -$591.4M | -$368.3M | -$198.5M | -$68.0M | -$224.2M |
| Working Capital | $104.3M | $554.7M | $351.9M | $174.6M | $38.7M | $213.3M |
Financial Health
| Debt / Equity | 0.05 |
| Current Ratio | 5.87 |
Profitability
| Return on Equity | -59.73% |
| Return on Invested Capital | -59.39% |
| Return on Assets | -49.04% |
| Gross Margin | 91.35% |
| Operating Margin | -192.81% |
| Net Margin | -183.90% |
Related companies: CCCC · CDXS · GNFT · IMDX · NTHI · OABI · OBIO
Explore sector: Healthcare · Biotechnology
More sections of IVVD: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks